Seeking Alpha

QualityStocks'  Instablog

Send Message
QualityStocks ( assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Cardium Therapeutics, Inc. (CXM) Written Up By Major Biotech Publisher 0 comments
    Oct 15, 2012 5:27 PM | about stocks: CXM

    A recent article in Genetic Engineering & Biotechnology News, the world's number one biotech publisher, carried a good report on Cardium Therapeutics and Generx, a Cardium product candidate. Generx is a DNA-based angiogenic growth factor therapeutic used to stimulate the growth of supplemental collateral blood vessels in the hearts of patients with advanced coronary artery disease. Superior to medicines that only provide transient relief of symptoms, Generx is designed to actually enhance myocardial blood flow in heart patients without having to resort to invasive surgical procedures. Availability of such a treatment option is especially important in many parts of the world where more elaborate procedures are not readily available or affordable.

    The article explains how patients with coronary artery disease (angina) have had the Generx Ad5FGF-4 vector infused into their coronary arteries. Cardium researchers found that patients with more severe coronary artery disease responded better than those with less severe disease. The fact that a medicine's effectiveness increases with the severity of disease might be considered encouraging, but researchers wanted to know why this was happening. They found that multiple blockages in a coronary artery, like a prolonged blockage, causes vasodilation, exposing more vessels and more surface area, along with increased vessel permeability. This allows enhanced Generx uptake, increasing its effectiveness. More importantly, the Coxsackie Adenovirus Receptor (NASDAQ:CAR), normally buried in the tight junction, is exposed.

    Gabor Rubanyi, M.D., Ph.D., and CSO of Cardium Therapeutics, summarized the finding: "When there is ischemia or any injury, then these tight junctions loosen up and these proteins all of a sudden are exposed and can bind the virus. Transfection starts with adenovirus fiber protein attaching to this receptor."

    It's a good example of Cardium's ongoing efforts to understand the underlying nature of genes and the human body, allowing improvements and new discoveries that continue to drive the company's progress.

    For additional information, visit

    Please see disclaimer on the QualityStocks website:

    Stocks: CXM
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.